A Phase 2 interventional study of Omaveloxolone Ophthalmic Suspension 1.0% and Omaveloxolone Opthalmic Suspension 0.5% in Inflammation and Pain Following Ocular Surgery, sponsored by Biogen. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
Following ophthalmic surgery, the current standard of care includes a topical ophthalmic corticosteroid or other anti-inflammatory agent to treat ocular inflammation and improve patient comfort. If left untreated, inflammation of the eye may result in further ocular complications including scarring, vision loss, or blindness. Although the exact dosing regimen is physician-dependent, patients are typically prescribed a topical corticosteroid for a period of 2-4 weeks following surgery, being tapered over the course of delivery as the inflammation subsides. Topical anti-inflammatory agents are usually administered multiple times per day, particularly in the early period following ophthalmic surgery. Continuing efforts in drug development aim to identify alternatives to ophthalmic corticosteroid use, due to their well-known local and systemic negative side effects.
3,541 studies on the registry are indexed under Inflammation; 645 are open to participants now.
This study's enrollment of 109 is above the median of 50 across 2,581 interventional studies indexed under Inflammation.
Browse Inflammation studies →Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Compared within Inflammation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 1.0% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
Drug: Omaveloxolone Ophthalmic Suspension 1.0%
Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 0.5% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
Drug: Omaveloxolone Opthalmic Suspension 0.5%
Patients will receive a single drop of vehicle for Omaveloxolone Ophthalmic suspension was instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
Drug: Placebo
Also known as: RTA 408
Also known as: RTA 408
Absence of Anterior Chamber Cells at Day 15 (Visit 5)
Count of participants who had absence of anterior chamber cells at Day 15. White blood cells were counted. In a healthy eye, the anterior chamber should not have any blood cells present. "Yes" indicates an absence of anterior chamber cells. Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.
Time frame: 15 days after the participant receives the first dose
Absence of Ocular Pain at Day 4 (Visit 3)
Participants were asked to report their pain on Day 4 using the Numerical Pain Rating Scale (NPRS) for patients receiving active drug compared to patients receiving placebo. The NPRS is an 11-point numeric scale, which ranges from "0" representing "no pain" to "10" representing the "worst pain imaginable". Lower scores indicate less pain. Participants reporting '0' were recorded as "Yes" while patients reporting any other pain score were recorded as "No". Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.
Time frame: 4 days after the participant receives the first dose
| Milestone | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo |
|---|---|---|---|
| Started | 37 | 33 | 39 |
| Completed treatment | 19 | 15 | 25 |
| Completed | 37 | 33 | 39 |
| Not completed | 0 | 0 | 0 |
Count of participants who had absence of anterior chamber cells at Day 15. White blood cells were counted. In a healthy eye, the anterior chamber should not have any blood cells present. "Yes" indicates an absence of anterior chamber cells. Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.
| Participants | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo |
|---|---|---|---|
| Yes | 10 | 12 | 11 |
| No | 27 | 21 | 28 |
Participants were asked to report their pain on Day 4 using the Numerical Pain Rating Scale (NPRS) for patients receiving active drug compared to patients receiving placebo. The NPRS is an 11-point numeric scale, which ranges from "0" representing "no pain" to "10" representing the "worst pain imaginable". Lower scores indicate less pain. Participants reporting '0' were recorded as "Yes" while patients reporting any other pain score were recorded as "No". Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.
| Participants | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo |
|---|---|---|---|
| Yes | 11 | 9 | 20 |
| No | 26 | 24 | 19 |
Collected over From Day 1 (24 +/- 6 hours after surgery) to Day 21. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Omaveloxolone Ophthalmic Suspension 1.0%: Study Eye | 0/37 (0%) | 0/37 (0%) | 18/37 (48.6%) |
| Omaveloxolone Ophthalmic Suspension 1.0%: Non-study Eye | 0/37 (0%) | 0/37 (0%) | 0/37 (0%) |
| Omaveloxolone Ophthalmic Suspension 0.5%: Study Eye | 0/33 (0%) | 0/33 (0%) | 15/33 (45.5%) |
| Omaveloxolone Ophthalmic Suspension 0.5%: Non-study Eye | 0/33 (0%) | 0/33 (0%) | 2/33 (6.1%) |
| Placebo: Study Eye | 0/39 (0%) | 0/39 (0%) | 13/39 (33.3%) |
| Placebo: Non-study Eye | 0/39 (0%) | 0/39 (0%) | 1/39 (2.6%) |
| Omaveloxolone Ophthalmic Suspension 1.0%: Non-ocular AE | 0/37 (0%) | 0/37 (0%) | 2/37 (5.4%) |
| Omaveloxolone Ophthalmic Suspension 0.5%: Non-ocular AE | 0/33 (0%) | 0/33 (0%) | 2/33 (6.1%) |
| Placebo: Non-ocular AE | 0/39 (0%) | 0/39 (0%) | 1/39 (2.6%) |
| Event | Omaveloxolone Ophthalmic Suspension 1.0%: Study Eye | Omaveloxolone Ophthalmic Suspension 1.0%: Non-study Eye | Omaveloxolone Ophthalmic Suspension 0.5%: Study Eye | Omaveloxolone Ophthalmic Suspension 0.5%: Non-study Eye | Placebo: Study Eye | Placebo: Non-study Eye | Omaveloxolone Ophthalmic Suspension 1.0%: Non-ocular AE | Omaveloxolone Ophthalmic Suspension 0.5%: Non-ocular AE | Placebo: Non-ocular AE |
|---|---|---|---|---|---|---|---|---|---|
| Conjunctival hyperaemiaEye disorders | 11/37 | 0/37 | 9/33 | 0/33 | 7/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| Corneal oedemaEye disorders | 3/37 | 0/37 | 5/33 | 0/33 | 1/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| Corneal disorderEye disorders | 4/37 | 0/37 | 1/33 | 0/33 | 0/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| Eye painEye disorders | 4/37 | 0/37 | 1/33 | 0/33 | 1/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| PhotophobiaEye disorders | 2/37 | 0/37 | 3/33 | 0/33 | 4/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| Corneal striaeEye disorders | 2/37 | 0/37 | 3/33 | 0/33 | 3/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| Visual acuity reducedEye disorders | 2/37 | 0/37 | 3/33 | 1/33 | 1/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| Eye irritationEye disorders | 2/37 | 0/37 | 2/33 | 0/33 | 0/39 | 0/39 | 0/37 | 0/33 | 0/39 |
| HeadacheNervous system disorders | 0/37 | 0/37 | 0/33 | 0/33 | 0/39 | 0/39 | 1/37 | 2/33 | 0/39 |
| Corneal depositsEye disorders | 2/37 | 0/37 | 0/33 | 0/33 | 0/39 | 0/39 | 0/37 | 0/33 | 0/39 |
Intent-to-treat population (all randomized patients with available data)
| Age, Continuous(years) | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo | Total |
|---|---|---|---|---|
| Mean | 67.9 ± 9.7 | 68.1 ± 9.31 | 68.9 ± 9.47 | 68.3 ± 9.42 |
| Sex: Female, Male(Participants) | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo | Total |
|---|---|---|---|---|
| Female | 23 | 18 | 20 | 61 |
| Male | 14 | 15 | 19 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 2 | 13 |
| Not Hispanic or Latino | 30 | 28 | 37 | 95 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 3 | 2 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 3 | 15 |
| White | 27 | 24 | 34 | 85 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Omaveloxolone Ophthalmic Suspension 1.0% | Omaveloxolone Ophthalmic Suspension 0.5% | Placebo | Total |
|---|---|---|---|---|
| United States | 37 | 33 | 39 | 109 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Feb 2014 to primary completion in Sep 2014, 7 months.
Results were first posted in Apr 2023, 8 years 6 months after primary completion. A results delay was requested in Oct 2014.
Of 36 industry-sponsored phase 2 interventional studies under Inflammation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.
Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omaveloxolone